AAPL343.37+3.29 (+0.97%) ▲|ABBV265.81+2.61 (+0.99%) ▲|ABT108.74+1.47 (+1.37%) ▲|ACN174.95+10.29 (+6.25%) ▲|ADBE264.54+15.36 (+6.16%) ▲|AMAT450.72-25.74 (-5.40%) ▼|AMD438.41-16.21 (-3.57%) ▼|AMGN389.84-3.26 (-0.83%) ▼|AMT173.52+2.02 (+1.18%) ▲|AMZN231.30+0.44 (+0.19%) ▲|AVGO377.12-3.80 (-1.00%) ▼|AXP333.13-3.51 (-1.04%) ▼|BA215.89-5.68 (-2.56%) ▼|BAC61.60-1.03 (-1.64%) ▼|BKNG204.03+4.72 (+2.37%) ▲|BLK1,098.17+0.62 (+0.06%) ▲|BMY63.67+0.07 (+0.10%) ▲|BNY153.55-2.95 (-1.88%) ▼|BRK-B510.63-1.75 (-0.34%) ▼|C127.65-4.83 (-3.64%) ▼|CAT781.26-59.60 (-7.09%) ▼|CL93.31+0.58 (+0.62%) ▲|CMCSA24.85+0.66 (+2.71%) ▲|COF210.38-2.03 (-0.96%) ▼|COP118.22+4.12 (+3.61%) ▲|COST974.80+8.22 (+0.85%) ▲|CRM189.06+7.56 (+4.17%) ▲|CSCO114.03-1.56 (-1.35%) ▼|CVS106.54-2.80 (-2.56%) ▼|CVX191.72+4.14 (+2.21%) ▲|DE614.72-25.13 (-3.93%) ▼|DHR198.11-0.94 (-0.47%) ▼|DIS98.89+0.00 (+0.00%) ▲|DUK129.38+0.14 (+0.11%) ▲|EMR146.87-4.94 (-3.25%) ▼|FDX309.34-3.31 (-1.06%) ▼|GD388.52-4.67 (-1.19%) ▼|GE353.79-9.80 (-2.70%) ▼|GEV906.96-36.42 (-3.86%) ▼|GILD134.43+0.11 (+0.08%) ▲|GM91.16+0.86 (+0.95%) ▲|GOOG338.98+6.38 (+1.92%) ▲|GOOGL339.83+6.12 (+1.83%) ▲|GS991.09-42.25 (-4.09%) ▼|HD340.69-3.78 (-1.10%) ▼|HON243.80-3.26 (-1.32%) ▼|IBM228.83+1.28 (+0.56%) ▲|INTC83.98-2.32 (-2.69%) ▼|INTU335.65+22.66 (+7.24%) ▲|ISRG354.36-7.44 (-2.06%) ▼|JNJ266.31-0.42 (-0.16%) ▼|JPM347.40-9.92 (-2.77%) ▼|KO89.12+0.85 (+0.96%) ▲|LIN511.51+0.33 (+0.06%) ▲|LLY1,218.56-2.11 (-0.17%) ▼|LMT576.19-5.12 (-0.88%) ▼|LOW217.71-0.53 (-0.24%) ▼|LRCX258.45-11.16 (-4.14%) ▼|MA566.34+3.59 (+0.64%) ▲|MCD272.04-0.99 (-0.36%) ▼|MDLZ65.20+2.72 (+4.35%) ▲|MDT87.62+0.74 (+0.85%) ▲|META593.40-0.02 (0.00%) ▼|MMM179.43-3.05 (-1.67%) ▼|MO75.17+0.35 (+0.47%) ▲|MRK131.08-0.74 (-0.56%) ▼|MS204.67-6.91 (-3.27%) ▼|MSFT398.10+4.75 (+1.21%) ▲|MU763.76-56.78 (-6.92%) ▼|NEE88.83-0.45 (-0.50%) ▼|NFLX73.58+1.19 (+1.64%) ▲|NKE43.17+0.12 (+0.27%) ▲|NOW116.38+5.76 (+5.21%) ▲|NVDA192.84-4.17 (-2.12%) ▼|ORCL119.28-0.69 (-0.57%) ▼|PEP144.34+1.48 (+1.04%) ▲|PFE25.20-0.06 (-0.22%) ▼|PG145.07-3.82 (-2.56%) ▼|PLTR125.19+1.66 (+1.34%) ▲|PM199.72-0.46 (-0.23%) ▼|QCOM160.70-2.19 (-1.34%) ▼|RTX218.92+0.34 (+0.16%) ▲|SBUX104.02+0.92 (+0.89%) ▲|SCHW105.62-0.35 (-0.33%) ▼|SO96.21-0.57 (-0.59%) ▼|SPG237.38+0.68 (+0.29%) ▲|T24.33-0.34 (-1.36%) ▼|TMO571.53-4.88 (-0.85%) ▼|TMUS182.00-0.39 (-0.21%) ▼|TSLA302.43-5.01 (-1.63%) ▼|TXN275.59-1.49 (-0.54%) ▼|UBER71.36+0.62 (+0.88%) ▲|UNH421.63-7.16 (-1.67%) ▼|UNP291.27-3.18 (-1.08%) ▼|UPS104.26-1.28 (-1.21%) ▼|USB63.17-1.26 (-1.96%) ▼|V368.81+2.22 (+0.61%) ▲|VZ48.40+0.21 (+0.43%) ▲|WFC84.44-2.43 (-2.80%) ▼|WMT114.08+0.98 (+0.87%) ▲|XOM156.55+3.51 (+2.29%) ▲|AAPL343.37+3.29 (+0.97%) ▲|ABBV265.81+2.61 (+0.99%) ▲|ABT108.74+1.47 (+1.37%) ▲|ACN174.95+10.29 (+6.25%) ▲|ADBE264.54+15.36 (+6.16%) ▲|AMAT450.72-25.74 (-5.40%) ▼|AMD438.41-16.21 (-3.57%) ▼|AMGN389.84-3.26 (-0.83%) ▼|AMT173.52+2.02 (+1.18%) ▲|AMZN231.30+0.44 (+0.19%) ▲|AVGO377.12-3.80 (-1.00%) ▼|AXP333.13-3.51 (-1.04%) ▼|BA215.89-5.68 (-2.56%) ▼|BAC61.60-1.03 (-1.64%) ▼|BKNG204.03+4.72 (+2.37%) ▲|BLK1,098.17+0.62 (+0.06%) ▲|BMY63.67+0.07 (+0.10%) ▲|BNY153.55-2.95 (-1.88%) ▼|BRK-B510.63-1.75 (-0.34%) ▼|C127.65-4.83 (-3.64%) ▼|CAT781.26-59.60 (-7.09%) ▼|CL93.31+0.58 (+0.62%) ▲|CMCSA24.85+0.66 (+2.71%) ▲|COF210.38-2.03 (-0.96%) ▼|COP118.22+4.12 (+3.61%) ▲|COST974.80+8.22 (+0.85%) ▲|CRM189.06+7.56 (+4.17%) ▲|CSCO114.03-1.56 (-1.35%) ▼|CVS106.54-2.80 (-2.56%) ▼|CVX191.72+4.14 (+2.21%) ▲|DE614.72-25.13 (-3.93%) ▼|DHR198.11-0.94 (-0.47%) ▼|DIS98.89+0.00 (+0.00%) ▲|DUK129.38+0.14 (+0.11%) ▲|EMR146.87-4.94 (-3.25%) ▼|FDX309.34-3.31 (-1.06%) ▼|GD388.52-4.67 (-1.19%) ▼|GE353.79-9.80 (-2.70%) ▼|GEV906.96-36.42 (-3.86%) ▼|GILD134.43+0.11 (+0.08%) ▲|GM91.16+0.86 (+0.95%) ▲|GOOG338.98+6.38 (+1.92%) ▲|GOOGL339.83+6.12 (+1.83%) ▲|GS991.09-42.25 (-4.09%) ▼|HD340.69-3.78 (-1.10%) ▼|HON243.80-3.26 (-1.32%) ▼|IBM228.83+1.28 (+0.56%) ▲|INTC83.98-2.32 (-2.69%) ▼|INTU335.65+22.66 (+7.24%) ▲|ISRG354.36-7.44 (-2.06%) ▼|JNJ266.31-0.42 (-0.16%) ▼|JPM347.40-9.92 (-2.77%) ▼|KO89.12+0.85 (+0.96%) ▲|LIN511.51+0.33 (+0.06%) ▲|LLY1,218.56-2.11 (-0.17%) ▼|LMT576.19-5.12 (-0.88%) ▼|LOW217.71-0.53 (-0.24%) ▼|LRCX258.45-11.16 (-4.14%) ▼|MA566.34+3.59 (+0.64%) ▲|MCD272.04-0.99 (-0.36%) ▼|MDLZ65.20+2.72 (+4.35%) ▲|MDT87.62+0.74 (+0.85%) ▲|META593.40-0.02 (0.00%) ▼|MMM179.43-3.05 (-1.67%) ▼|MO75.17+0.35 (+0.47%) ▲|MRK131.08-0.74 (-0.56%) ▼|MS204.67-6.91 (-3.27%) ▼|MSFT398.10+4.75 (+1.21%) ▲|MU763.76-56.78 (-6.92%) ▼|NEE88.83-0.45 (-0.50%) ▼|NFLX73.58+1.19 (+1.64%) ▲|NKE43.17+0.12 (+0.27%) ▲|NOW116.38+5.76 (+5.21%) ▲|NVDA192.84-4.17 (-2.12%) ▼|ORCL119.28-0.69 (-0.57%) ▼|PEP144.34+1.48 (+1.04%) ▲|PFE25.20-0.06 (-0.22%) ▼|PG145.07-3.82 (-2.56%) ▼|PLTR125.19+1.66 (+1.34%) ▲|PM199.72-0.46 (-0.23%) ▼|QCOM160.70-2.19 (-1.34%) ▼|RTX218.92+0.34 (+0.16%) ▲|SBUX104.02+0.92 (+0.89%) ▲|SCHW105.62-0.35 (-0.33%) ▼|SO96.21-0.57 (-0.59%) ▼|SPG237.38+0.68 (+0.29%) ▲|T24.33-0.34 (-1.36%) ▼|TMO571.53-4.88 (-0.85%) ▼|TMUS182.00-0.39 (-0.21%) ▼|TSLA302.43-5.01 (-1.63%) ▼|TXN275.59-1.49 (-0.54%) ▼|UBER71.36+0.62 (+0.88%) ▲|UNH421.63-7.16 (-1.67%) ▼|UNP291.27-3.18 (-1.08%) ▼|UPS104.26-1.28 (-1.21%) ▼|USB63.17-1.26 (-1.96%) ▼|V368.81+2.22 (+0.61%) ▲|VZ48.40+0.21 (+0.43%) ▲|WFC84.44-2.43 (-2.80%) ▼|WMT114.08+0.98 (+0.87%) ▲|XOM156.55+3.51 (+2.29%) ▲|
26.8 C
New York
Wednesday, July 29, 2026

Tag: TRI

newssourceFORcompanyinformationcontent1releasesmarket

/C O R R E C T I O N — AMPERA/

In the news release, AMPERA Establishes Australian Subsidiary to Secure Thorium Supply and Support U.S. Advanced Nuclear Fuel Production, issued 08-Jun-2026 by AMPERA over...

AMPERA Establishes Australian Subsidiary to Secure Thorium Supply and Support U.S. Advanced Nuclear Fuel Production

PALM BEACH GARDENS, Fla., June 9, 2026 /PRNewswire/ -- AMPERA today announced its factory-built, scalable, supercritical nuclear energy system will be fueled by thorium...

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical...

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /CNW/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers